ABIVAX Société Anonyme discovers and optimizes drugs for the treatment of inflammatory diseases, infectious diseases, and cancer in France. Its principal products include ABX464 that is in Phase IIb clinical trials for the treatment of ulcerative colitis and Crohn's Disease, as well as for COVID-19; Phase IIa clinical trial for the treatment of rheumatoid arthritis diseases; and has completed Phase IIa clinical trial for the treatment of viral remission in patients with HIV. It also develops ABX 196, an immune enhancer candidate that is in Phase 1/2 clinical trials for the treatment of hepatocellular cancer. In addition, the company engages in the research programs for the treatment of Dengue fever, influenza, and respiratory syncytial virus. ABIVAX Société Anonyme has license contracts with the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. The company was incorporated in 2013 and is headquartered in Paris, France.

Mr. Didier  Blondel

EVice President, Chief Financial Officer & Board Secretary

Mr. Sheldon  Sloan M.D.

Chief Medical Officer

Mr. Patrick  Malloy

Senior Vice President of Investor Relations

Ms. Ida  Hatoum

Chief People Officer

Mr. Marc M. P. de Garidel M.B.A.

Chief Executive Officer & Interim Chair of Board

Dr. Philippe  Pouletty M.D., Ph.D.

Founder & Director

Mr. Pierre  Courteille M.B.A.

Chief Business Officer

Mr. Michael  Ferguson B.S., M.B.A.

Chief Commercial Officer

Mr. Didier  Scherrer Ph.D.

Chief Scientific Officer

Mr. Jérôme  Denis

Executive Vice President of Process Development & Manufacturing

ABIVAX Société Anonyme

ABIVAX Société Anonyme 経営体制

経営情報